OptiNose to begin Phase III trials with intranasal technology
The review has been completed and the FDA has notified the company to proceed with the studies related to IND. The company is expected to initiate Phase III
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).